Structural basis of IL-23 antagonism by an Alphabody protein scaffold

Nature Communications

Volumn 5, Issue , 2014, Pages

  Desmet, Johan ^a   Verstraete, Kenneth ^b   Bloch, Yehudi ^b   Lorent, Eric ^a   Wen, Yurong ^b   Devreese, Bart ^b   Vandenbroucke, Karen ^a   Loverix, Stefan ^a   Hettmann, Thore ^a   Deroo, Sabrina ^a   Somers, Klaartje ^a   Henderikx, Paula ^a   Lasters, Ignace ^a   Savvides, Savvas N ^b  

^a Complix NV Technology Park 4 ^*  (Belgium)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHABODY PROTEIN SCAFFOLD; CYTOKINE RECEPTOR AFFECTING AGENT; EPITOPE; GLUTAMINE; INTERLEUKIN 12P40; INTERLEUKIN 23; INTERLEUKIN 23P19; ISOLEUCINE; POLYPEPTIDE; SCAFFOLD PROTEIN; SIGNAL RECOGNITION PARTICLE; TRYPTOPHAN; TYROSINE; UNCLASSIFIED DRUG; PEPTIDE;

ANTIBODY; BIOTECHNOLOGY; CRYSTAL STRUCTURE; DISEASE TREATMENT; IMMUNITY; PHYSICOCHEMICAL PROPERTY; PROTEIN;

AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; BINDING AFFINITY; BIOPANNING; CIRCULAR DICHROISM; CONSENSUS SEQUENCE; CONTROLLED STUDY; CRYSTAL STRUCTURE; CRYSTALLIZATION; DRUG DESIGN; ENZYME LINKED IMMUNOSORBENT ASSAY; GEL PERMEATION CHROMATOGRAPHY; HEK293 CELL LINE; HUMAN; HUMAN CELL; HYDROGEN BOND; HYDROPHOBICITY; ISOTHERMAL TITRATION CALORIMETRY; LYMPHOMA CELL LINE; MASS SPECTROMETRY; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PHYSICAL CHEMISTRY; PROTEIN DENATURATION; PROTEIN FOLDING; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN SUBUNIT; PROTEIN TARGETING; PSORIASIS; STOP CODON; SURFACE PLASMON RESONANCE; TRIPLE HELIX; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL LINE; CHEMISTRY; MALE; MOLECULAR GENETICS; PRECLINICAL STUDY;

AMINO ACID SEQUENCE; ANIMALS; CELL LINE; DRUG EVALUATION, PRECLINICAL; HUMANS; INTERLEUKIN-23; MALE; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; PEPTIDES; PSORIASIS;

EID: 84923238605     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms6237     Document Type: Article

References (61)

1. Chan, A. C. & Carter, P. J. Therapeutic antibodies for autoimmunity and inflammation. Nat. Rev. Immunol. 10, 301-316 (2010).
2. Page, D. B., Postow, M. A., Callahan, M. K., Allison, J. P. & Wolchok, J. D. Immune modulation in cancer with antibodies. Annu. Rev. Med. 65, 185-202 (2014).
3. Smith, M. C. & Gestwicki, J. E. Features of protein-protein interactions that translate into potent inhibitors: topology, surface area and affinity. Expert Rev. Mol. Med. 14, e16 (2012).
4. Wells, J. A. & McClendon, C. L. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 450, 1001-1009 (2007).
5. Der, B. S. & Kuhlman, B. Strategies to control the binding mode of de novo designed protein interactions. Curr. Opin. Struct. Biol. 23, 639-646 (2013).
6. Gilbreth, R. N. & Koide, S. Structural insights for engineering binding proteins based on non-antibody scaffolds. Curr. Opin. Struct. Biol. 22, 413-420 (2012).
7. Wurch, T., Pierre, A. & Depil, S. Novel protein scaffolds as emerging therapeutic proteins: from discovery to clinical proof-of-concept. Trends Biotechnol. 30, 575-582 (2012).
8. Binz, H. K., Amstutz, P. & Pluckthun, A. Engineering novel binding proteins from nonimmunoglobulin domains. Nat. Biotechnol. 23, 1257-1268 (2005).
9. Koide, A. & Koide, S. Monobodies: antibody mimics based on the scaffold of the fibronectin type III domain. Methods Mol. Biol. 352, 95-109 (2007).
10. Schonfeld, D. et al. An engineered lipocalin specific for CTLA-4 reveals a combining site with structural and conformational features similar to antibodies. Proc. Natl Acad. Sci. USA 106, 8198-8203 (2009).
11. Hoyer, W., Gronwall, C., Jonsson, A., Stahl, S. & Hard, T. Stabilization of a beta-hairpin in monomeric Alzheimer's amyloid-beta peptide inhibits amyloid formation. Proc. Natl Acad. Sci. USA 105, 5099-5104 (2008).
12. Mouratou, B. et al. Remodeling a DNA-binding protein as a specific in vivo inhibitor of bacterial secretin PulD. Proc. Natl Acad. Sci. USA 104, 17983-17988 (2007).
13. Lipovsek, D. Adnectins: engineered target-binding protein therapeutics. Protein Eng. Des. Sel. 24, 3-9 (2011).
14. Desmet, J., Lasters, I. & Loverix, S. Single-chain antiparallel coiled coil proteins. US patent US 20110294983 A1 (2011).
15. Benson, J. M. et al. Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab. Nat. Biotechnol. 29, 615-624 (2011).
16. Lowes, M. A., Suarez-Farinas, M. & Krueger, J. G. Immunology of psoriasis. Annu. Rev. Immunol. 32, 227-255 (2014).
17. Duerr, R. H. et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 314, 1461-1463 (2006).
18. Murphy, C. A. et al. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J. Exp. Med. 198, 1951-1957 (2003).
19. Langowski, J. L. et al. IL-23 promotes tumour incidence and growth. Nature 442, 461-465 (2006).
20. Teng, M. W. et al. Opposing roles for IL-23 and IL-12 in maintaining occult cancer in an equilibrium state. Cancer Res. 72, 3987-3996 (2012).
21. Vignali, D. A. & Kuchroo, V. K. IL-12 family cytokines: immunological playmakers. Nat. Immunol. 13, 722-728 (2012).
22. Beyer, B. M. et al. Crystal structures of the pro-inflammatory cytokine interleukin-23 and its complex with a high-affinity neutralizing antibody. J. Mol. Biol. 382, 942-955 (2008).
23. Luo, J. et al. Structural basis for the dual recognition of IL-12 and IL-23 by ustekinumab. J. Mol. Biol. 402, 797-812 (2010).
24. Lupardus, P. J. & Garcia, K. C. The structure of interleukin-23 reveals the molecular basis of p40 subunit sharing with interleukin-12. J. Mol. Biol. 382, 931-941 (2008).
25. Elliott, M. et al. Ustekinumab: lessons learned from targeting interleukin-12/23p40 in immune-mediated diseases. Ann. N.Y. Acad. Sci. 1182, 97-110 (2009).
26. Krueger, G. G. et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. New Engl. J. Med. 356, 580-592 (2007).
27. Leonardi, C. L. et al. Efficacy and safety of ustekinumab, a human interleukin- 12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 371, 1665-1674 (2008).
28. Papp, K. A. et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 371, 1675-1684 (2008).
29. Reddy, M. et al. Positive treatment effects of ustekinumab in psoriasis: analysis of lesional and systemic parameters. J. Dermatol. 37, 413-425 (2010).
30. Colombo, M. P. & Trinchieri, G. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 13, 155-168 (2002).
31. Xu, M. et al. Regulation of antitumor immune responses by the IL-12 family cytokines, IL-12, IL-23, and IL-27. Clin. Dev. Immunol. 2010, 832454 (2010).
32. Woolfson, D. N., Bartlett, G. J., Bruning, M. & Thomson, A. R. New currency for old rope: from coiled-coil assemblies to alpha-helical barrels. Curr. Opin. Struct. Biol. 22, 432-441 (2012).
33. Testa, O. D., Moutevelis, E. & Woolfson, D. N. CC + : a relational database of coiled-coil structures. Nucleic Acids Res. 37, D315-D322 (2009).
34. Desmet, J. & Lasters, I. Non-natural proteinaceous scaffold made of three noncovalently associated peptides, US patent US20100305304 (2010).
35. Harbury, P. B., Zhang, T., Kim, P. S. & Alber, T. A switch between two-, three-, and four-stranded coiled coils in GCN4 leucine zipper mutants. Science 262, 1401-1407 (1993).
36. Lovejoy, B., Cascio, D. & Eisenberg, D. Crystal structure of canine and bovine granulocyte-colony stimulating factor (G-CSF). J. Mol. Biol. 234, 640-653 (1993).
37. Steiner, D., Forrer, P., Stumpp, M. T. & Pluckthun, A. Signal sequences directing cotranslational translocation expand the range of proteins amenable to phage display. Nat. Biotechnol. 24, 823-831 (2006).
38. Schierle, C. F. et al. The DsbA signal sequence directs efficient, cotranslational export of passenger proteins to the Escherichia coli periplasm via the signal recognition particle pathway. J. Bacteriol. 185, 5706-5713 (2003).
39. Shan, S.-o. & Walter, P. Co-translational protein targeting by the signal recognition particle. FEBS Lett. 579, 921-926 (2005).
40. Aggarwal, S., Ghilardi, N., Xie, M. H., de Sauvage, F. J. & Gurney, A. L. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J. Biol. Chem. 278, 1910-1914 (2003).
41. Gallagher, G., Yu, R. & Brazaitis, J. Novel polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof. US Patent US20130029907 A1 (2013).
42. Clarke, A. W. et al. A novel class of anti-IL-12p40 antibodies: potent neutralization via inhibition of IL-12-IL-12Rbeta2 and IL-23-IL-23R. mAbs 2, 539-549 (2010).
43. Lindroos, J. et al. IL-23-mediated epidermal hyperplasia is dependent on IL-6. J. Invest. Dermatol. 131, 1110-1118 (2011).
44. Chang, V. T. et al. Glycoprotein structural genomics: solving the glycosylation problem. Structure 15, 267-273 (2007).
45. Ramamurthy, V. et al. Structures of adnectin/protein complexes reveal an expanded binding footprint. Structure 20, 259-269 (2012).
46. Doucey, M. A., Hess, D., Blommers, M. J. & Hofsteenge, J. Recombinant human interleukin-12 is the second example of a C-mannosylated protein. Glycobiology 9, 435-441 (1999).
47. de Beer, T., Vliegenthart, J. F., Loffler, A. & Hofsteenge, J. The hexopyranosyl residue that is C-glycosidically linked to the side chain of tryptophan-7 in human RNase Us is alpha-mannopyranose. Biochemistry 34, 11785-11789 (1995).
48. Sidhu, S. S. Antibodies for all: The case for genome-wide affinity reagents. FEBS Lett. 586, 2778-2779 (2012).
49. Arrowsmith, J. & Miller, P. Trial watch: phase II and phase III attrition rates 2011-2012. Nat. Rev. Drug Discov. 12, 569 (2013).
50. Schellekens, H. How to predict and prevent the immunogenicity of therapeutic proteins. Biotechnol. Annu. Rev. 14, 191-202 (2008).
51. Brinks, V., Jiskoot, W. & Schellekens, H. Immunogenicity of therapeutic proteins: the use of animal models. Pharm. Res. 28, 2379-2385 (2011).
52. Karanicolas, J. et al. A de novo protein binding pair by computational design and directed evolution. Mol. Cell 42, 250-260 (2011).
53. Marks, J. D. et al. By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J. Mol. Biol. 222, 581-597 (1991).
54. Aricescu, A. R. et al. Eukaryotic expression: developments for structural proteomics. Acta Crystallogr. D Biol. Crystallogr. 62, 1114-1124 (2006).
55. Kabsch, W. XDS. Acta Crystallogr. D Biol. Crystallogr. 66, 125-132 (2010).
56. McCoy, A. J. Solving structures of protein complexes by molecular replacement with Phaser. Acta Crystallogr. D Biol. Crystallogr. 63, 32-41 (2007).
57. Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486-501 (2010).
58. Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66, 213-221 (2010).
59. Krissinel, E. & Henrick, K. Inference of macromolecular assemblies from crystalline state. J. Mol. Biol. 372, 774-797 (2007).
60. The PyMOL Molecular Graphics System, Version 1.6.0 Schrödinger, LLC. (2010).
61. Geromanos, S. J. et al. The detection, correlation, and comparison of peptide precursor and product ions from data independent LC-MS with data dependant LC-MS/MS. Proteomics 9, 1683-1695 (2009).